Education
About Us
Working with TipRanks
Follow Us
Simulations Plus (SLP)
:SLP
SLP Stock Chart & Stats
$17.31
-$4.39(-14.45%)
At close: 4:00 PM EST
$17.31
-$4.39(-14.45%)
Day’s Range― - ―
52-Week Range$12.39 - $37.67
Previous CloseN/A
Volume738.72K
Average Volume (3M)408.45K
Market Cap
$395.64M
Enterprise Value$253.61M
Total Cash (Recent Filing)$28.45M
Total Debt (Recent Filing)$719.00K
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Jan 14, 2026EPS EstimateN/A
Last Dividend Ex-Date
Jul 29, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding20,144,564
10 Day Avg. Volume447,358
30 Day Avg. Volume408,451
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.28
Price to Sales (P/S)3.60
P/FCF Ratio16.36
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue3.16
Enterprise Value/Gross Profit5.87
Enterprise Value/Ebitda18.45
Forecast
1Y Price Target
$20.50Price Target Upside18.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI InnovationSimulations Plus is well positioned to capitalize on the eventual rebound, especially as the company invests to incorporate more AI solutions across its product portfolio.
Financial PerformanceShares of Simulations Plus are up almost 16% currently on the back of the company’s solid top- and bottom-line beat in the quarter and slightly better-than-expected fiscal 2026 outlook.
Market ExpansionThe market is expanding, and its software capabilities are increasing to capture more market share.
Bears Say
Customer Spending SlowdownBiopharma customer spending slowdown tied to macro concerns about geopolitical uncertainties, tariffs, and drug pricing have resulted in lighter-than-expected service revenues for SLP.
Renewal Rate DeclineRenewal rates dropped to 83% for the quarter due to client consolidations and site closures, impacting the company's revenue stability.
Revenue DeclineF1Q:26 revenue is expected to decline by (3) - (5)% y/y, in part due to seasonality.
Simulations Plus News
SLP FAQ
What was Simulations Plus’s price range in the past 12 months?
Simulations Plus lowest stock price was $12.39 and its highest was $37.66 in the past 12 months.
What is Simulations Plus’s market cap?
Simulations Plus’s market cap is $395.64M.
When is Simulations Plus’s upcoming earnings report date?
Simulations Plus’s upcoming earnings report date is Jan 14, 2026 which is in 37 days.
How were Simulations Plus’s earnings last quarter?
Simulations Plus released its earnings results on Oct 22, 2025. The company reported $0.1 earnings per share for the quarter, missing the consensus estimate of $0.185 by -$0.085.
Is Simulations Plus overvalued?
According to Wall Street analysts Simulations Plus’s price is currently Undervalued.
Does Simulations Plus pay dividends?
Simulations Plus pays a Quarterly dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Simulations Plus dividends here
What is Simulations Plus’s EPS estimate?
Simulations Plus’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Simulations Plus have?
Simulations Plus has 20,144,564 shares outstanding.
What happened to Simulations Plus’s price movement after its last earnings report?
Simulations Plus reported an EPS of $0.1 in its last earnings report, missing expectations of $0.185. Following the earnings report the stock price went down -2.213%.
Which hedge fund is a major shareholder of Simulations Plus?
Currently, no hedge funds are holding shares in SLP
Simulations Plus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.50 (18.43% Upside)
$20.50 (18.43% Upside)
Blogger Sentiment
Bullish
SLP Sentiment 70%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 74.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.35%
12-Months-Change
Fundamentals
Return on Equity
-42.13%
Trailing 12-Months
Asset Growth
-36.46%
Trailing 12-Months
Company Description
Simulations Plus
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
SLP Company Deck
SLP Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture for Simulations Plus. While the fiscal year showed notable revenue growth and strategic advancements in their unified operating model, the fourth quarter faced revenue declines and challenges in the Pro-ficiency segment. The financial position remains strong, but the net loss due to a significant impairment charge and lower renewal rates are concerning. Overall, the company is positioned for future growth with strategic initiatives, but current market challenges and financial setbacks temper the outlook.View all SLP earnings summariesSLP Stock 12 Month Forecast
Average Price Target
$20.50
▲(18.43% Upside)
Technical Analysis
Ownership Overview
17.29% Insiders
23.48% Mutual Funds
18.33% Other Institutional Investors
31.58% Public Companies and
Individual Investors